about
All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines.Replication and transmission of mammalian-adapted H9 subtype influenza virus in pigs and quailDevelopment of an Alternative Modified Live Influenza B Virus Vaccine.Oral Fluids as a Live-Animal Sample Source for Evaluating Cross-Reactivity and Cross-Protection following Intranasal Influenza A Virus Vaccination in Pigs.The Molecular Determinants of Antibody Recognition and Antigenic Drift in the H3 Hemagglutinin of Swine Influenza A Virus.Construction and characterisation of a complete reverse genetics system of dengue virus type 3.Widespread Virus Replication in Alveoli Drives Acute Respiratory Distress Syndrome in Aerosolized H5N1 Influenza Infection of Macaques.Reverse Genetics of Influenza B Viruses.Short- and long-term protective efficacy against clade 2.3.4.4 H5N2 highly pathogenic avian influenza virus following prime-boost vaccination in turkeys.A two-plasmid strategy for engineering a dengue virus type 3 infectious clone from primary Brazilian isolate.Plasmid-Based Reverse Genetics of Influenza A Virus.Development and characterization of a packaging cell line for pseudo-infectious yellow fever virus particle generation.An alternative strategy as a quadrivalent live attenuated influenza virus vaccinePlasticity of amino acid residue 145 near the receptor binding site of H3 swine influenza A viruses and its impact on receptor binding and antibody recognitionComparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A VirusesAge-dependent pathogenesis of clade 2.3.4.4A H5N2 HPAIV in experimentally infected Broad Breasted White turkeysFlexibility of Amino Acid 226 in the Receptor-Binding Site of an H9 Subtype Influenza A Virus and Its Effect on Virus Replication, Tropism, and TransmissionEnhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particlesOutflanking immunodominance to target subdominant broadly neutralizing epitopes
P50
Q30363730-F8206911-B8CD-49FE-902B-F814801FFF0CQ30374791-B5844BF8-B6D8-447D-95F6-8ACE6B8B151CQ33733453-0B7EBEC9-5B3F-4CB5-AE2A-D0CEF22F0BD9Q36087562-FBFC7E6C-40EE-419E-AC56-55A2DF64D758Q37224897-1E033202-3BF4-4867-A6AD-AF3CECE4D429Q37734118-69D9F1C7-2142-4A47-BAF1-4A1516C018F0Q39034871-3A350C72-CB32-4E90-B5C0-86E3E51B1213Q39309001-C8DEA14A-0F63-4F64-9559-0FC6BEA61AC5Q40050369-3044DD5F-B155-4E6F-B17E-46844D24ACA5Q40173737-A205DB6D-F283-4FC5-AFE2-9C8B8BB1A1E5Q40200014-E14E9E3B-DC01-4605-B4C9-2A8D3B913D27Q53532467-A1AA62C3-ECD8-4EBE-A43A-9D6441140AC0Q57093877-F983FF86-2677-4F35-84BE-1E644BD0673EQ57793046-0BA71470-7B86-496E-B406-4A4AF2E8F4B4Q58706119-0D20091D-479C-4974-B3D8-7D5E4B2BE906Q63880142-3592E22A-90F4-40F4-9276-FA3F31ADFB1FQ63880149-A3C4BCCB-151B-43D5-8EDB-C09402390920Q91238196-CEE89436-9F8A-4EA7-BB8E-8B2932B496A2Q92859858-1C9B7632-BC8A-4CD6-9B6E-997C0E247898
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jefferson José da Silva Santos
@ast
Jefferson José da Silva Santos
@en
Jefferson José da Silva Santos
@es
Jefferson José da Silva Santos
@nl
type
label
Jefferson José da Silva Santos
@ast
Jefferson José da Silva Santos
@en
Jefferson José da Silva Santos
@es
Jefferson José da Silva Santos
@nl
prefLabel
Jefferson José da Silva Santos
@ast
Jefferson José da Silva Santos
@en
Jefferson José da Silva Santos
@es
Jefferson José da Silva Santos
@nl
P106
P1153
55964647600
P21
P31
P496
0000-0001-5895-4163